by mediaid pharmacy | Jan 28, 2026 | Blogs
Cancer care has advanced significantly with the introduction of targeted therapies and PARP inhibitors. One such trusted oncology medicine is Niranib 140 mg (Niraparib), widely used in the management of ovarian and related cancers. This blog provides an expert-level...
by mediaid pharmacy | Jan 27, 2026 | Blogs
Sunitinib 50 mg (Sunitix) is a widely prescribed targeted cancer therapy used in the treatment of several advanced and metastatic cancers. As a multi-targeted tyrosine kinase inhibitor (TKI), it plays a critical role in modern oncology by disrupting tumor blood supply...
by mediaid pharmacy | Jan 27, 2026 | Blogs
Crizotinib 250mg (Crizonix) is a targeted cancer therapy widely prescribed for specific types of non-small cell lung cancer (NSCLC). As a tyrosine kinase inhibitor (TKI), it plays a critical role in precision oncology by blocking abnormal proteins that drive cancer...
by mediaid pharmacy | Jan 26, 2026 | Blogs
Regonix 40mg (Regorafenib) is a targeted oral anti-cancer medication widely prescribed in advanced or treatment-resistant cancers. It belongs to the class of multikinase inhibitors, designed to suppress tumor growth, angiogenesis, and cancer cell proliferation. This...
by mediaid pharmacy | Jan 24, 2026 | Blogs
Afanix 40 mg (Afatinib) is an advanced targeted cancer therapy widely prescribed for the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. Manufactured under strict pharmaceutical standards, Afanix Tablet 40 mg belongs to the class of...
by mediaid pharmacy | Jan 24, 2026 | Blogs
Ibrutix 140 mg is a targeted oral cancer medication containing Ibrutinib, widely prescribed for several blood-related malignancies. It belongs to the class of Bruton’s Tyrosine Kinase (BTK) inhibitors, offering precision-based therapy with proven clinical outcomes....
